Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to evaluate the effects of yoga (including breathing exercises) on the quality of life in patients, diagnosed and undergoing standard treatments for non-small cell lung cancer.

Clinical Trial Description

This clinical trial studies yoga in improving quality of life in patients with non-small cell lung cancer undergoing treatment. Yoga may help improve quality of life and pulmonary functional capacity in patients with non-small cell lung cancer. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

NCT number NCT02895503
Study type Interventional
Source Virginia Commonwealth University
Status Terminated
Phase N/A
Start date January 2012
Completion date August 2013

See also
  Status Clinical Trial Phase
Recruiting NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Not yet recruiting NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT01871805 - A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Phase 2
Recruiting NCT02777567 - KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
Recruiting NCT03215693 - X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib Phase 2
Not yet recruiting NCT03539536 - Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer Phase 2
Recruiting NCT03247309 - TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) Phase 1
Recruiting NCT02920450 - Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) Phase 1/Phase 2
Completed NCT00341380 - Prevention of Tumor Spread Due to Lung Cancer Surgery
Active, not recruiting NCT02848651 - A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT02468661 - A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Phase 1/Phase 2
Recruiting NCT03178552 - A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3
Not yet recruiting NCT03624907 - Daily vs. Non-Daily SBRT for NSCLC N/A
Recruiting NCT02760225 - Pembrolizumab-PET Imaging N/A
Active, not recruiting NCT02933346 - Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program N/A
Not yet recruiting NCT02795923 - Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT02906150 - Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type Phase 2